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Health Insurance database, 2009), costs of care in community and in institution 
(French National Assembly on AD management, report 2005). Results were reported 
in EUR 2009. Health-related utilities were obtained from preceding published eco-
nomic evaluations in AD (Getsios et al 2001). Costs and QALYs were discounted at 
annual rates of 0% (base-case analysis), 3% and 5%. Deterministic and probabilistic 
sensitivity analyses were carried out to test the robustness of model assumptions. 
RESULTS: Over the seven-year time horizon, patients treated with ChEI monotherapy 
spent on average 41.6 months before institutionalization. Overall costs were c72,469 
(health care system perspective) or c89,735 (societal perspective). QALYs were esti-
mated at 2.36. Memantine as adjunct therapy to ChEI was associated with a longer 
time to nursing home of 8.9 months, QALYs gains of 0.19 and a cost saving of c5900 
(health care system perspective) or c2200 (societal perspective), i.e. a dominant treat-
ment scenario versus ChEI monotherapy. CONCLUSIONS: This economic evaluation 
suggest that, from both a health care system and a societal perspective, memantine as 
adjunct therapy to ChEI is a cost-effective strategy in the management of AD patients 
compared with ChEI monotherapy.
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OBJECTIVES: Methylprednisolone sodium succinate (MP) is an acute therapeutic 
option for traumatic spinal cord injury (SCI). a pivotal multicentre randomized control 
trial reported modest functional improvements and increased clinical complications 
associated with an extended dose regimen of MP for 48 hours (48h-MP) versus a 
limited dose regimen of MP for 24 hours (24h-MP), resulting in clinical ambiguity 
between 48h-MP and 24h-MP. Concerning the health care burden imposed by this 
devastating form of neurotrauma, an economic assessment comparing the beneﬁ ts 
either MP regimen imparts has never been reported. We performed a cost-effectiveness 
analysis (CEA) of 48h-MP compared with 24h-MP to determine their impact on direct 
health care costs for this patient population. METHODS: A decision tree model, 
incorporating motor improvement and complication frequencies reported by the Third 
National Acute Spinal Cord Injury Study and utility scores (QALYs) obtained from 
an Australian cohort, measured outcomes and effects at 6 and 12 months post-injury. 
Survival data, direct health care expenditures and complication costs associated with 
SCI and MP intervention were obtained from published epidemiological and survey 
data. CEA was performed from the health care payer’s perspective, discounted at a 
rate of 4% annually with a lifetime horizon. Distributions of the incremental cost-
effectiveness ratio between the interventions were determined by Monte Carlo simula-
tion. The model was validated with sensitivity analyses by varying costs and outcome 
comparators. RESULTS: As a result, 48h-MP dominates 24h-MP, providing higher 
QALYs at lower costs. The lower costs associated with 48h-MP intervention was 
$35,703 per patient lifecycle. Earlier motor improvement maintained at 1-year post-
injury was a key variable favouring 48h-MP intervention, despite complications asso-
ciated with this dosing regimen. CONCLUSIONS: To conclude, 48h-MP is the 
cost-effective intervention for SCI in comparison to 24h-MP, wherein the former 
results in modestly improved motor function, an effect which is maintained up to at 
least 1-year post-injury.
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OBJECTIVES: To conduct a German economic evaluation of natalizumab compared 
to other disease modifying drugs (DMD) in relapsing-remitting Multiple Sclerosis (MS) 
from a societal perspective. METHODS: A Markov model was designed to compare 
costs and outcomes of Natalizumab (Nb), other DMD (interferon-beta, glatiramer 
acetate) and best supportive care (BSC). The expanded disability status scale (EDSS) 
and the line of treatment were used to deﬁ ne the distinctive Markov States. Transition 
probabilities for progression, treatment switches and withdrawals were derived from 
clinical studies and literature. German real-life treatment data of MS-patients under 
DMD were collected retrospectively (N = 554) and used to validate assumptions and 
conduct sensitivity analyses. Cost data and quality of life estimates were taken from 
a European burden of MS study. a time horizon of 30 years and annual discount rates 
of 3% for costs and outcomes were chosen. RESULTS: Treatment with Nb resulted 
in 8.13 avoided relapses over 30 years, and in 2.36 avoided relapses under other DMD. 
After 30 years, the proportion of surviving patients at a low state of disease (incl. 
EDSS 4) was 59% for the Nb group, 31% for the other DMD and 8% for patients 
in the BSC group. The average MS related costs over 30 years were estimated at 
c847,160 for Nb, c816,139 for other DMD, and c627,701 for BSC. Cost per quality 
adjusted life-year (QALY) was c60,938 for Nb, c64,481 for other DMD and c53,911 
for BSC. The incremental cost-effectiveness of Nb compared to other DMD was 
c24,919 per QALY. CONCLUSIONS: MS is a resource intense disease due to its 
chronic course and its severe impact on patients’ daily life. Long term analysis suggests 
that even treatment without DMD is expensive and leads to considerable inferior 
clinical outcomes. Treatment with DMD improves the situation of patients, with 
Natalizumab showing the highest efﬁ cacy and best cost-effectiveness ratio.
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OBJECTIVES: Parkinson’s Disease (PD) is both a chronic and progressive neurode-
generative disorder. a 24-hour prolonged release tablet (PR) of the dopamine agonist 
ropinirole was introduced next to three daily doses of ropinirole immediate release 
(IR). a randomized controlled trial (PREPARED) was conducted, comparing ropini-
role-IR with ropinirole-PR. Ropinirole-PR signiﬁ cantly improved the off-time and this 
analysis assesses the costs-effectiveness of the ropinirole-PR in PD patients who are 
not adequately controlled on L-dopa compated to ropinirole-IR. METHODS: A 
Markov-health-state-transition model was used with health states combining off-time 
≤25% and >25% per day, Hoehn & Yahr stages 2–5 and problematic dyskinesias. 
Time horizons are 5 years and lifelong. Costs and effects were discounted by 4% and 
1,5% respectively. Healthcare perspective was taken, covering direct costs related to 
medication, consults, nursing and patient care including informal care, based on an 
ongoing Dutch observational study in PD (IMPACT study). Clinical outcomes from 
the PREPARED-trial are extrapolated based on literature assumptions. Results are 
presented as incremental costs and QALY’s gained. Both univariate and probabilistic 
sensitivity analyses (PSA) were performed. RESULTS: Ropinirole-PR was associated 
with lower L-dopa use, less off-time and less problematic dyskinesias. This resulted 
in incremental QALY gains of 0.125 and 0.336 over respectively 5 years and lifetime. 
The health care costs per H&Y-stage increased with disease severity and amounted 
c916, c1,492, c11,295 and c11.295 for stage 2 to 5 over 6 months. Treatment with 
ropinirole-PR was more costly than ropinirole-IR with a difference of c7.266 over 5 
years and c17.773 over lifetime. Treatment with ropinirole-PR however reduced 
medical costs by c8,059 over 5 years and c69,532 over lifetime compared with rop-
inirol-IR, mainly due to reduced dyskinesia occurrence. Sensitivity analysis conﬁ rmed 
the robustness of the model. CONCLUSIONS: Patient-functioning and quality of life 
were improved with ropinirole-PR realizing cost-savings to the health care budget as 
compared to treatment with ropinirole-IR.
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BACKGROUND: Parkinson’s Disease (PD) is a central nervous system disorder 
caused by progressive deterioration of brain areas that produce dopamine. Oral 
dopaminergic therapies control the symptoms of the disease, but these require three 
or more times daily doses, so it is associated with poor compliance or adherence, 
which affects the overall efﬁ cacy and costs in health. OBJECTIVES: To analyze the 
cost-effectiveness of rotigotine versus pramipexole in patients with PD in Mexico. 
METHODS: We conducted an economic evaluation. The alternatives to compare were 
rotigotine 4, 6, 8 and 12  mg administered once daily versus pramipexole 3 mg/d and 
another scenario versus pramipexole 4.5 mg/d. The perspective is the Mexican Social 
Security Institute. The model included the cost of drug acquisition and management 
of adverse events (AE) for a 22 weeks period. The measure of efﬁ cacy was compliance 
or adherence to treatment, as a direct comparison study of rotigotine versus prami-
pexole demonstrated non-inferiority between the two alternatives. RESULTS: The 
compliance rate for rotigotine was 81% vs. 61% pramipexole. The costs were 
US$748, US$920, US$1113 and US$1701 for rotigotine 4, 6, 8 and 12 mg/d respec-
tively, compared with US$670 and US$967 for pramipexole 3 and 4.5 mg/d. The cost 
per successfully treated patient was lower for rotigotine 4, 6 and 8 mg/d (US$923, 
US$1 136 and US$1374, respectively) than with pramipexole 4.5 mg/d (US$1585). 
Rotigotine 4, 6, 8 and 12 mg/d were found to be a highly cost-effective strategy 
compared with pramipexole 3 and 4.5 mg/d, according to WHO criteria. CONCLU-
SIONS: The results of this analysis suggest that the use of rotigotine in patients with 
PD, represents a highly cost-effective strategy or cost saving for the public health 
institutions in Mexico. Rotigotine is an innovative alternative for easy administration 
(transdermal).
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OBJECTIVES: This study aimed to compare the cost-effectiveness (CE) of Bridion® 
(sugammadex) with neostigmine and spontaneous recovery (SR) approach in the 
reversal of neuromuscular blockade (NMB) induced by rocuronium/vecuronium, 
during anesthesia. METHODS: CE analysis (CEA) was performed by solving back 
the decision tree that included pathways starting with residual NMB and followed by 
hypoxia and pulmonary complications deﬁ ned as “aspiration, atelectasis and/or pneu-
monia” in patients, in whom NMB was induced by rocuronium/vecuronium. Bridion 
was compared with neostigmine and SR approach. Primary analysis parameters that 
